GlassScriptPhysician profile
James Priola
NPI 1306879838
$15,115.00
in general payments reported to CMS, 2019-2025
68 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,339 · 2020: $1,295 · 2021: $2,234 · 2022: $1,861 · 2023: $1,879 · 2024: $1,923 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,386.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,351.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,887.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,740.59 | 2019-2025 | |
| Pfizer INC. | $843.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.38 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $711.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $589.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $562.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $380.98 | 2019-2024 | Xarelto, Spravato |
| Astellas Pharma US INC | $370.13 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $363.23 | 2019-2023 | Verquvo, Pneumovax 23, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.52 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $297.37 | 2019-2024 | |
| Allergan, INC. | $268.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.95 | 2019-2021 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Priola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.